CU20090116A7 - PHARMACEUTICAL PREPARATION TO REDUCE ENDOMETRIOSIS - Google Patents
PHARMACEUTICAL PREPARATION TO REDUCE ENDOMETRIOSISInfo
- Publication number
- CU20090116A7 CU20090116A7 CU20090116A CU20090116A CU20090116A7 CU 20090116 A7 CU20090116 A7 CU 20090116A7 CU 20090116 A CU20090116 A CU 20090116A CU 20090116 A CU20090116 A CU 20090116A CU 20090116 A7 CU20090116 A7 CU 20090116A7
- Authority
- CU
- Cuba
- Prior art keywords
- pharmaceutical composition
- endometriosis
- negative influence
- bone density
- pharmaceutical preparation
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title abstract 3
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 230000037182 bone density Effects 0.000 abstract 2
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 206010003497 Asphyxia Diseases 0.000 abstract 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 230000004097 bone metabolism Effects 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 229960000978 cyproterone acetate Drugs 0.000 abstract 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 abstract 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 abstract 1
- 229960003309 dienogest Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composición farmacéutica para el tratamiento de endometriosis sin reducir la densidad ósea contiene un gestágeno con eficacia antiandrogénica, con preferencia 17 alfa-cianometil-17-beta-hidroxiestra-4,9-dien-3-ona (dienogest), acetato de ciproterona o acetato de cloromadinona en una dosis diaria que es como máximo el doble de la dosis inhibidora de la ovulación, junto con uno o varios excipientes/portadores farmacéuticamente aceptables. La composición farmacéutica según la invención produce tanto la reducción de la endometriosis como también la ausencia de influencia negativa sobre el metabolismo óseo y de la densidad ósea y al mismo tiempo puede mantener en una medida tolerable los efectos colaterales conocidos de los medicamentos convencionales (por ejemplo, sofocaciones, acné, influencia negativa del perfil lipídico). La composición farmacéutica es por ello apropiada para la aplicación a largo plazo.A pharmaceutical composition for the treatment of endometriosis without reducing bone density contains a gestagen with antiandrogenic efficacy, preferably 17 alpha-cyanomethyl-17-beta-hydroxystetra-4,9-dien-3-one (dienogest), cyproterone acetate or Chloromadinone acetate in a daily dose that is at most double the ovulation inhibitor dose, together with one or more pharmaceutically acceptable excipients / carriers. The pharmaceutical composition according to the invention produces both the reduction of endometriosis as well as the absence of negative influence on bone metabolism and bone density and at the same time can maintain to a tolerable extent the known side effects of conventional medications (for example , suffocations, acne, negative influence of the lipid profile). The pharmaceutical composition is therefore appropriate for long-term application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20090116A CU20090116A7 (en) | 2009-07-03 | 2009-07-03 | PHARMACEUTICAL PREPARATION TO REDUCE ENDOMETRIOSIS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20090116A CU20090116A7 (en) | 2009-07-03 | 2009-07-03 | PHARMACEUTICAL PREPARATION TO REDUCE ENDOMETRIOSIS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20090116A7 true CU20090116A7 (en) | 2011-07-11 |
Family
ID=44306217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20090116A CU20090116A7 (en) | 2009-07-03 | 2009-07-03 | PHARMACEUTICAL PREPARATION TO REDUCE ENDOMETRIOSIS |
Country Status (1)
| Country | Link |
|---|---|
| CU (1) | CU20090116A7 (en) |
-
2009
- 2009-07-03 CU CU20090116A patent/CU20090116A7/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115939A2 (en) | COMPOSITION CONTAINING ULTRA-MICRONIZED PALMITOYL-ETHANOLAMIDE | |
| UY33343A (en) | ORAL SOLID DOSAGE FORMS WITH VERY LOW DOSE FOR HRT | |
| ECSP088123A (en) | ORAL CONTRACEPTION WITH TRIMEGESTONE | |
| MX2012003551A (en) | Orally transformable tablets. | |
| NO20091954L (en) | Use of ostradiol valerate or 17β-ostradil in combination with dienogest for oral therapy to maintain and / or increase female libido | |
| ES2916649T1 (en) | Compositions and uses for the treatment of multiple sclerosis | |
| CL2011003291A1 (en) | Single-dose pharmaceutical composition containing a) as gestagen 50-90 µg of levonorgestrel and b) as cox inhibitor (cyclooxygenase) 5-60 mg of piroxicam, 50-600 mg of indomethacin or 40-450 mg of diclofenac; and its use to prepare drugs for contraception in an emergency. | |
| CO6400186A2 (en) | ULIPRISTAL ACETATE TABLETS | |
| UY35624A (en) | USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE | |
| ES2693085T1 (en) | Use of estriol in low doses | |
| CL2007003604A1 (en) | Pharmaceutical composition for oral administration comprising the amorphous 17-aminogeldanamycin compound; and its use in the treatment of cancer. | |
| ECSP10010224A (en) | LUTEINIZING HORMONE LIQUID FORMULATIONS (LH). | |
| MX392839B (en) | SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT. | |
| ECSP099482A (en) | PHARMACEUTICAL PREPARATION TO REDUCE ENDOMETRIOSIS | |
| UY32650A (en) | MEDICINAL ORAL ADMINISTRATION CONTAINING AT LEAST ONE STEROGEN AND / OR AT LEAST A GESTAGEN AND AT LEAST A PROBIOTIC BACTERIA CEPA | |
| CO2019000604A2 (en) | Vaginal composition comprising a combination of estrogen and vitamin D | |
| GT200900296A (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIVE AGENT. | |
| CU20090116A7 (en) | PHARMACEUTICAL PREPARATION TO REDUCE ENDOMETRIOSIS | |
| CU20110070A6 (en) | METHOD FOR TREATING ENDOMETRIOSIS WITHOUT DECREASING BONE DENSITY | |
| AR080541A1 (en) | TREATMENT FOR ENDOMETRIOSIS | |
| MX2009008813A (en) | PHARMACEUTICAL COMPOSITION CONTAINING FLOROGLUCINOL AND PARACETAMOL. | |
| CR9324A (en) | PHARMACEUTICAL PREPARATION FOR ORAL ANTI-CONCEPTION | |
| AR053546A1 (en) | SOLID PERORAL PHARMACOLOGICAL FORM FOR ANTI-CONCEPTION | |
| AR070023A1 (en) | USE OF GESTAGENS IN COMBINATION WITH (6S) -5-METHYL-TETRAHYDROPHOLATE FOR THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPEUTIC COLLATERAL EFFECTS AND REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS AT THE BEGINNING OF BEGIN | |
| CU20090062A7 (en) | USE OF ESTRADIOL VALERATE OR 17BETA-ESTRADIOL IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR INCREASE THE FEMALE LIBID |